Modifications to induction therapy decrease risk of early death in infants with acute lymphoblastic leukemia treated on Children's Oncology Group P9407

Pediatric Blood and Cancer

Volumn 59, Issue 5, 2012, Pages 834-839

  Salzer, Wanda L ^a   Jones, Tamekia L ^b   Devidas, Meenakshi ^b   Hilden, Joanne M ^c   Winick, Naomi ^d   Hunger, Stephen ^c   Carroll, William L ^e   Camitta, Bruce ^f   Dreyer, Zoann E ^g  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c CHILDREN S HOSPITAL COLORADO   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e NEW YORK UNIVERSITY   (United States)

^f MEDICAL COLLEGE OF WISCONSIN   (United States)

^g TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

Infant acute lymphoblastic leukemia; Mortality

Indexed keywords

AMPHOTERICIN B; ANTHRACYCLINE; ASPARAGINASE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; FLUCONAZOLE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; METHOTREXATE; PENTAMIDINE; PREDNISONE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AGE DISTRIBUTION; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BLEEDING; CANCER MORTALITY; CAUSE OF DEATH; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SUBSTITUTION; FEVER; HERPES ZOSTER; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFANT; MAJOR CLINICAL STUDY; MORBIDITY; MUCOSA INFLAMMATION; MYCOSIS; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; SEIZURE; SEPSIS; SKIN TOXICITY; STOMATITIS; THROMBOSIS; TREATMENT OUTCOME; VIRUS INFECTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DAUNORUBICIN; DEXAMETHASONE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDNISOLONE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 84866147739     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24132     Document Type: Article

References (47)

1. Hunger S, Devidas M, Camitta B, et al. Improved survival for children with acute lymphoblastic leukemia (ALL) from 1990-2005: A report from the Children's Oncology Group (COG). 3-6 Oct 2008. Berlin, Germany: Wiley-Liss, Inc.; p. 31.
2. Schrappe M, Nachman J, Hunger S, et al. Educational symposium on long-term results of large prospective clinical trials for childhood acute lymphoblastic leukemia (1985-2000). Leukemia 2010; 24: 253-254.
3. Moricke A, Zimmermann M, Reiter A, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 2009; 24: 265-284.
4. Silverman LB, Stevenson KE, O'Brien JE, et al. Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). Leukemia 2009; 24: 320-334.
5. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009; 360: 2730-2741.
6. Seibel NL, Steinherz PG, Sather HN, et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: A report from the Children's Oncology Group. Blood 2008; 111: 2548-2555.
7. Matloub Y, Bostrom BC, Hunger SP, et al. Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: A report from the Children's Oncology Group. Blood 2011; 118: 243-251.
8. Reaman G, Zeltzer P, Bleyer WA, et al. Acute lymphoblastic leukemia in infants less than one year of age: A cumulative experience of the Children's Cancer Study Group. J Clin Oncol 1985; 3: 1513-1521.
9. Chessells JM, Eden OB, Bailey CC, et al. Acute lymphoblastic leukaemia in infancy: Experience in MRC UKALL trials. Report from the Medical Research Council Working Party on Childhood Leukaemia. Leukemia 1994; 8: 1275-1279.
10. Frankel LS, Ochs J, Shuster JJ, et al. Therapeutic trial for infant acute lymphoblastic leukemia: The Pediatric Oncology Group experience (POG 8493). J Pediatr Hematol Oncol 1997; 19: 35-42.
11. Dordelmann M, Reiter A, Borkhardt A, et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood 1999; 94: 1209-1217.
12. Reaman GH, Sposto R, Sensel MG, et al. Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group. J Clin Oncol 1999; 17: 445-455.
13. Hilden JM, Dinndorf PA, Meerbaum SO, et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: Report on CCG 1953 from the Children's Oncology Group. Blood 2006; 108: 441-451.
14. Tomizawa D, Koh K, Sato T, et al. Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: A final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group. Leukemia 2007; 21: 2258-2263.
15. Pieters R, Schrappe M, De Lorenzo P, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): An observational study and a multicentre randomised trial. Lancet 2007; 370: 240-250.
16. Silverman LB, McLean TW, Gelber RD, et al. Intensified therapy for infants with acute lymphoblastic leukemia: Results from the Dana-Farber Cancer Institute Consortium. Cancer 1997; 80: 2285-2295.
17. Ferster A, Bertrand Y, Benoit Y, et al. Improved survival for acute lymphoblastic leukaemia in infancy: The experience of EORTC-Childhood Leukaemia Cooperative Group. Br J Haematol 1994; 86: 284-290.
18. Igarashi S, Manabe A, Ohara A, et al. No advantage of dexamethasone over prednisolone for the outcome of standard- and intermediate-risk childhood acute lymphoblastic leukemia in the Tokyo Children's Cancer Study Grou L95-14 Protocol. J Clin Oncol 2005; 23: 6489-6498.
19. Dreyer ZE, Dinndorf PA, Camitta B, et al. Analysis of the role of hematopoietic stem-cell transplantation in infants with acute lymphoblastic leukemia in first remission and MLL gene rearrangements: A report from the Children's Oncology Group. J Clin Oncol 2011; 29: 214-222.
20. Bostrom BC, Erdmann GR, Kamen BA. Systemic methotrexate exposure is greater after intrathecal than after oral administration. J Pediatr Hematol Oncol 2003; 25: 114-117.
21. Mitchell CD, Richards SM, Kinsey SE, et al. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: Results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 2005; 129: 734-745.
22. Schrappe M, Zimmermann M, Moricke A, et al. Dexamethasone in induction can eliminate one third of all relapses in childhood acute lymphoblastic leukemia (ALL): Results of an international randomized trial in 3655 patients (Trial AIEOP-BFM ALL 2000). ASH Annu Meet Abstr 2008; 112: 7.
23. Winick NJ, Salzer WL, Devidas M, et al. Dexamethasone (DEX) versus prednisone (PRED) during induction for children with high risk acute lymphoblastic leukemia (HR-ALL): A report from the Children's oncology group study AALL 0232. ASCO Meet Abstr 29: 9504.
24. Balis FM, Lester CM, Chrousos GP, et al. Differences in cerebrospinal fluid penetration of corticosteroids: Possible relationship to the prevention of meningeal leukemia. J Clin Oncol 1987; 5: 202-207.
25. Hortobagyi GN, Frye D, Buzdar AU, et al. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer 1989; 63: 37-45.
26. Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982; 96: 133-139.
27. Chauvenet AR, Martin PL, Devidas M, et al. Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: A report from Children's Oncology Group Study P9201. Blood 2007; 110: 1105-1111.
28. Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 2007; 109: 896-904.
29. Borowitz MJ, Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: A Children's Oncology Group study. Blood 2008; 111: 5477-5485.
30. Hurwitz CA, Silverman LB, Schorin MA, et al. Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. Cancer 2000; 88: 1964-1969.
31. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: Results of Dana-Farber Consortium Protocol 91-01. Blood 2001; 97: 1211-1218.
32. Ackland SP, Ratain MJ, Vogelzang NJ, et al. Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxorubicin. Clin Pharmacol Ther 1989; 45: 340-347.
33. Bielack SS, Erttmann R, Winkler K, et al. Doxorubicin: Effect of different schedules on toxicity and anti-tumor efficacy. Eur J Cancer Clin Oncol 1989; 25: 873-882.
34. Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: A report from the Children's Cancer Group. Blood 2003; 101: 3809-3817.
35. Vrooman LM, Neuberg DS, Stevenson KE, et al. Dexamethasone and individualized asparaginase dosing are each associated with superior event-free survival in childhood acute lymphoblastic leukemia: Results from DFCI-ALL Consortium Protocol 00-01. ASH Annu Meet Abstr 2009; 114: 321.
36. Teuffel O, Kuster SP, Hunger SP, et al. Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: A systematic review and meta-analysis. Leukemia 2011.
37. Lipshultz SE, Giantris AL, Lipsitz SR, et al. Doxorubicin administration by continuous infusion is not cardioprotective: The Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol. J Clin Oncol 2002; 20: 1677-1682.
38. Levitt GA, Dorup I, Sorensen K, et al. Does anthracycline administration by infusion in children affect late cardiotoxicity? Br J Haematol 2004; 124: 463-468.
39. Salzer W, Dinndorf P, Dreyer Z, et al. Analysis of infectious complications in infants with acute lymphoblastic leukemia treated on the Children's Cancer Group Protocol 1953 a report from the Children's Oncology Group. J Pediatr Hematol Oncol 2009; 31: 398-405.
40. Morselli PL. Clinical pharmacology of the perinatal period and early infancy. Clin Pharmacokinet 1989; 17: 13-28.
41. Kearns GL, Reed MD. Clinical pharmacokinetics in infants and children. A reappraisal. Clin Pharmacokinet 1989; 17: 29-67.
42. Guignard JP, Torrado A, Da Cunha O, et al. Glomerular filtration rate in the first three weeks of life. J Pediatr 1975; 87: 268-272.
43. Bartelink IH, Rademaker CM, Schobben AF, et al. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet 2006; 45: 1077-1097.
44. Anderson GD, Lynn AM. Optimizing pediatric dosing: A developmental pharmacologic approach. Pharmacotherapy 2009; 29: 680-690.
45. Haycock GB, Schwartz GJ, Wisotsky DH. Geometric method for measuring body surface area: A height-weight formula validated in infants, children, and adults. J Pediatr 1978; 93: 62-66.
46. Thyss A, Suciu S, Bertrand Y, et al. Systemic effect of intrathecal methotrexate during the initial phase of treatment of childhood acute lymphoblastic leukemia. The European Organization for Research and Treatment of Cancer Children's Leukemia Cooperative Group. J Clin Oncol 1997; 15: 1824-1830.
47. Hempel G, Relling MV, de Rossi G, et al. Pharmacokinetics of daunorubicin and daunorubicinol in infants with leukemia treated in the interfant 99 protocol. Pediatr Blood Cancer 2010; 54: 355-360.